Biomerica Inc (BMRA)vsMerck & Company Inc (MRK)
BMRA
Biomerica Inc
$2.51
+6.36%
HEALTHCARE · Cap: $10.28M
MRK
Merck & Company Inc
$146.87
-0.19%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1494825% more annual revenue ($66.57B vs $4.45M). MRK leads profitability with a 4.8% profit margin vs -84.8%. MRK earns a higher WallStSmart Score of 36/100 (F).
BMRA
Avoid24
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BMRA.
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$146.87
$63.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
16.8% revenue growth
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -125.8% — below average capital efficiency
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Revenue Growth. Revenue growth of 16.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BMRA profiles as a growth stock while MRK is a value play — different risk/reward profiles.
BMRA carries more volatility with a beta of 0.37 — expect wider price swings.
BMRA is growing revenue faster at 16.8% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology firm focused on developing and manufacturing cutting-edge diagnostic solutions catering to both medical and food industries. The company specializes in proprietary testing methods aimed at metabolic diseases, gastrointestinal disorders, and food intolerances, positioning itself to significantly enhance healthcare outcomes and diagnostic precision. With a commitment to addressing unmet medical needs, Biomerica capitalizes on strategic research partnerships and advanced technology integration, facilitating growth in the dynamic diagnostics market. Its patient-centric strategy further underscores the potential for transformative improvements in global healthcare diagnostics, making it a compelling prospect for institutional investors.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?